Therefore, they have different treatment characteristics: (1) CDK4/6 inhibitors (Palbociclib) are used in hormone receptor-positive breast cancer [10]; (2) treatments such as Trastuzumab are used in neoplasms with HER-2 overexpression [11]; (3) for triple-negative tumors, immunotherapy is used, which includes drugs such as Pembrolizumab, a monoclonal antibody targeting programmed cell death protein 1 (PD-1) [12]. This evidence concerns the gene PDCD1 and neoplasm.